Plain-English translation of NCT06146660 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a safety monitoring study of , a medication designed to treat obstructive hypertrophic cardiomyopathy — a condition where the heart muscle becomes too thick and makes it harder for the heart to pump blood. The study is being conducted in Korea and will follow 600 adults who are prescribed this medication to see how safe it is in real-world use.
was recently approved in Korea for this heart condition, and doctors and the medication company want to carefully monitor how safely it works when used by everyday patients in actual medical practice, rather than just in controlled research settings.
You likely qualify if…
You likely don't qualify if…
As a participant, you would take as prescribed by your doctor for your heart condition. The study team will collect information about your health and safety over time — likely through regular clinic visits and health record reviews — to monitor how well you tolerate the medication and whether you experience any side effects. This is an observational study, meaning you are not asked to do anything different than your normal medical care; researchers are simply watching and documenting your experience.
AI-generated summary from trial data · Aug 30, 2026 · Not medical advice
South Korea
Sponsor
Bristol-Myers Squibb
Enrollment target
~600 participants
Started
July 2024
Primary completion
November 2026
Age range
19 Years and older
Last updated on clinicaltrials.gov in November 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
BMS Study Connect Contact Center www.BMSStudyConnect.com
Bristol-Myers Squibb
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.